274 related articles for article (PubMed ID: 21921371)
1. Renovascular protective effects of erythropoietin in patients with chronic kidney disease.
Fujiwara N; Nakamura T; Sato E; Kawagoe Y; Hikichi Y; Ueda Y; Node K
Intern Med; 2011; 50(18):1929-34. PubMed ID: 21921371
[TBL] [Abstract][Full Text] [Related]
2. Effect of erythropoietin on urinary liver-type fatty-acid-binding protein in patients with chronic renal failure and anemia.
Nakamura T; Sugaya T; Kawagoe Y; Suzuki T; Ueda Y; Koide H
Am J Nephrol; 2006; 26(3):276-80. PubMed ID: 16772708
[TBL] [Abstract][Full Text] [Related]
3. Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease.
Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Ueda Y; Sugaya T; Yamagishi S; Yamada S; Koide H
Am J Med Sci; 2010 Feb; 339(2):157-63. PubMed ID: 20145433
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of recombinant human erythropoietin treatment in pre-dialysis patients: results of a multicenter study.
Albertazzi A; Di Liberato L; Daniele F; Battistel V; Colombi L
Int J Artif Organs; 1998 Jan; 21(1):12-8. PubMed ID: 9554820
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.
Palazzuoli A; Silverberg D; Iovine F; Capobianco S; Giannotti G; Calabrò A; Campagna SM; Nuti R
Am Heart J; 2006 Dec; 152(6):1096.e9-15. PubMed ID: 17161060
[TBL] [Abstract][Full Text] [Related]
6. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
[TBL] [Abstract][Full Text] [Related]
7. Human recombinant erythropoietin augments serum asymmetric dimethylarginine concentrations but does not compromise nitric oxide generation in mice.
Desai A; Zhao Y; Warren JS
Nephrol Dial Transplant; 2008 May; 23(5):1513-20. PubMed ID: 18204093
[TBL] [Abstract][Full Text] [Related]
8. Role of oxidative stress in cardiovascular effects of anemia treatment with erythropoietin in predialysis patients with chronic kidney disease.
Martinez-Vea A; Marcas L; Bardají A; Romeu M; Gutierrez C; García C; Compte T; Nogues R; Peralta C; Giralt M
Clin Nephrol; 2012 Mar; 77(3):171-81. PubMed ID: 22377247
[TBL] [Abstract][Full Text] [Related]
9. Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre-dialysis Japanese chronic kidney disease patients.
Hirakata H; Tsubakihara Y; Gejyo F; Nishi S; Iino Y; Watanabe Y; Suzuki M; Saito A; Akiba T; Inaguma D; Fukuhara S; Morita S; Hiroe M; Hada Y; Suzuki M; Akaishi M; Aonuma K; Akizawa T
Clin Exp Nephrol; 2010 Feb; 14(1):28-35. PubMed ID: 19763743
[TBL] [Abstract][Full Text] [Related]
10. Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner.
Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Ueda Y; Suzuki T; Ueda S; Adachi H; Okuda S; Yamagishi S
Pharmacol Res; 2009 Dec; 60(6):525-8. PubMed ID: 19409491
[TBL] [Abstract][Full Text] [Related]
11. Early responsiveness to continuous erythropoietin receptor activator predicts renal prognosis and is determined by a novel antioxidative marker in non-dialysis chronic kidney disease: a prospective, observational, single-center study.
Ino J; Kasama E; Kodama M; Harada T; Sato K; Eizumi H; Kawashima Y; Nitta K
Clin Exp Nephrol; 2020 Jul; 24(7):590-597. PubMed ID: 32185544
[TBL] [Abstract][Full Text] [Related]
12. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome.
Palazzuoli A; Silverberg DS; Iovine F; Calabrò A; Campagna MS; Gallotta M; Nuti R
Am Heart J; 2007 Oct; 154(4):645.e9-15. PubMed ID: 17892986
[TBL] [Abstract][Full Text] [Related]
13. Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure.
Nanayakkara PW; Teerlink T; Stehouwer CD; Allajar D; Spijkerman A; Schalkwijk C; ter Wee PM; van Guldener C
Kidney Int; 2005 Nov; 68(5):2230-6. PubMed ID: 16221223
[TBL] [Abstract][Full Text] [Related]
14. Oral adsorbent AST-120 ameliorates tubular injury in chronic renal failure patients by reducing proteinuria and oxidative stress generation.
Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Suzuki T; Ueda Y; Yamagishi S
Metabolism; 2011 Feb; 60(2):260-4. PubMed ID: 20189611
[TBL] [Abstract][Full Text] [Related]
15. Oral adsorbent AST-120 potentiates the effect of erythropoietin-stimulating agents on Stage 5 chronic kidney disease patients: a randomized crossover study.
Wu IW; Hsu KH; Sun CY; Tsai CJ; Wu MS; Lee CC
Nephrol Dial Transplant; 2014 Sep; 29(9):1719-27. PubMed ID: 24714415
[TBL] [Abstract][Full Text] [Related]
16. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
17. Brain natriuretic peptide as a potential novel marker of salt-sensitivity in chronic kidney disease patients without cardiac dysfunction.
Hayashi M; Yasuda Y; Suzuki S; Tagaya M; Ito T; Kamada T; Yoshinaga M; Sugishita Y; Fujiwara W; Yokoi H; Ozaki Y; Izawa H
Heart Vessels; 2017 Mar; 32(3):279-286. PubMed ID: 27385024
[TBL] [Abstract][Full Text] [Related]
18. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
Chen HH; Tarng DC; Lee KF; Wu CY; Chen YC
J Nephrol; 2008; 21(4):543-9. PubMed ID: 18651544
[TBL] [Abstract][Full Text] [Related]
19. Potential benefit of statin therapy for dyslipidemia with chronic kidney disease: Fluvastatin Renal Evaluation Trial (FRET).
Inoue T; Ikeda H; Nakamura T; Abe S; Taguchi I; Kikuchi M; Toyoda S; Miyazono M; Kishi T; Sanai T; Node K
Intern Med; 2011; 50(12):1273-8. PubMed ID: 21673461
[TBL] [Abstract][Full Text] [Related]
20. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease.
Nakamura T; Sugaya T; Kawagoe Y; Suzuki T; Ueda Y; Koide H; Inoue T; Node K
Am J Med Sci; 2007 Jun; 333(6):321-6. PubMed ID: 17570983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
